Alleviation of imiquimod-induced psoriasis-like symptoms in Rorα-deficient mouse skin

Koog Chan Park1, Jiwon Kim2, Aram Lee1

  • 1Research Institute of Women's Health, Sookmyung Women's University, Seoul 04310; Department of Biological Sciences, Cellular Heterogeneity Research Center, Sookmyung Women's University, Seoul 04310, Korea.

BMB Reports
|January 26, 2023
PubMed

Insights

Retinoic acid receptor-related orphan receptor α (RORα) deficiency alleviates psoriasis-like symptoms by reducing inflammation and keratinocyte hyperproliferation. RORα inhibition may offer a therapeutic strategy for treating psoriasis.

Area of Science:

  • Dermatology
  • Immunology
  • Molecular Biology

Background:

  • Retinoic acid receptor-related orphan receptor α (RORα) is involved in various physiological processes but its role in skin remains unclear.
  • RORα is expressed in epidermal layers, but its absence does not affect normal epidermal development.

Discussion:

  • RORα deficiency ameliorates psoriasis-like symptoms in mice, characterized by improved epidermal stratification and reduced keratinocyte proliferation.
  • A significant decrease in splenic Th17 cells was observed in RORα-deficient mice.
  • RORα deficiency suppresses imiquimod-induced activation of NF-κB and STAT3 pathways in keratinocytes.

Key Insights:

  • RORα plays a role in keratinocyte inflammatory responses and Th17 cell populations.
  • Targeting RORα could be a novel therapeutic approach for psoriasis.
  • RORα inhibitors may impact both immune cells and keratinocytes in psoriasis pathogenesis.

Outlook:

  • RORα inhibitors show potential for treating psoriasis by modulating immune responses and keratinocyte activity.
  • Further research is needed to explore RORα's precise mechanisms in skin inflammation.
  • RORα inhibition could be investigated as an adjuvant therapy in cancer immunotherapy.

Related Concept Videos